Objective: The aim of this study was to predict the discriminating prognostic power of the neutrophil-to-lymphocyte ratio for overall survival in patients with metastatic renal cell carcinoma and to make a new model using the neutrophil-to-lymphocyte ratio. Methods: From 2007 to 2014, 190 patients with metastatic renal cell carcinoma treated with either systemic immunotherapy or/and vascular endothelial growth factor-targeted therapy were enroled. A multivariable proportional hazard model was developed to investigate the effects of the neutrophil-to-lymphocyte ratio as predictive prognostic factors for overall survival. This new model was incorporated into the current Heng risk model to validate a modified prognostic classification for overall survival. Results: In multivariable analysis, a high neutrophil-to-lymphocyte ratio [hazard ratio (HR) = 1.65] was a significant independent predictor of shorter overall survival (P = 0.005). Additional neutrophil-to-lymphocyte ratio markers improved the discriminating power of the Heng risk classification, as compared to the existing classification model (C-statistic: 0.7198 vs. 0.6943, P = 0.008). The reclassification of patient prognostic categories using the new model showed a total overall net improvement of 61.4% (P < 0.001).
Introduction
Metastatic renal cell carcinoma (mRCC) tends to be unpredictable, with patients showing poor survival (5-year survival rate = 8%). With its complexity of patient-oriented stratification based on disease burden status, the prediction of clinical outcomes, in terms of survival, with different therapeutic responses for mRCC patients is critical. Therefore, clinicians stratify patients and determine the optimal therapeutic option based on several prognostic models, such as the International Metastatic Renal Cell Carcinoma Database Consortium Model, also known as the Heng risk model (1) . The Heng risk model takes into account the patient's clinical and laboratory characteristics to better predict prognostic risk and to improve patient risk stratification, which comprises of the Karnofsky performance status, corrected serum calcium levels, haemoglobin concentration, time from diagnosis to treatment, platelets and neutrophils as prognostic factors associated with survival (1) .
Through recent improvement in high-throughput screening and gene-related technologies, the pathophysiology of various cancers, including RCC, has been more thoroughly examined, leading to the discovery of many new prognostic biomarkers. One such discovery in RCC is the importance of the host inflammatory response in carcinogenesis and tumour progression (2, 3) . Tumours tend to create microenvironments where inflammatory cells proliferate and produce a greater amount of mediators (4) . Laboratory markers of systemic inflammation are among the many prognostic biomarkers identified in RCC, irrespective of the localized or metastatic state of the tumour. The C-reactive protein (5), Glasgow prognostic score (6, 7) , neutrophil-to-lymphocyte ratio (NLR) (8) , lymphocyte-tomonocyte ratio (9) and platelet-to-lymphocyte ratio (PLR) (10) have been identified as independent prognostic variables in treatmentnaïve RCC (1) , as well as other urological and non-urological malignancies, such as gastric, breast and colon cancer.
The assessment of inflammatory responses to tumours provides an easy and cost-effective application in clinical practice and provides potentially easily available objective information for clinicians. Therefore, this study investigated the prognostic value of systemic inflammatory markers and evaluated possible inflammatory markers that might improve stratification in the current Heng risk model to predict overall survival (OS) in patients with mRCC. We further stratified the intermediate risk group with the addition of significant inflammatory markers to make the new model to examine prognoses. 
Results

Of
Impact of risk factors on OS
After excluding Eastern Cooperative Oncology Group performance status (ECOG-PS)values, since they ranged from 0 to 1, as well as lactate dehydrogenase (LDH), since this information was missing in many of the patient medical records, the single-variable analysis of the new prognostic factors and the results of the multivariable factor +, median follow-up time among survivors; ECOG-PS, Eastern Cooperative Oncology Group performance status; 0: fully active, able to carry on all predisease performance without restriction, 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light house work, office work; LLN, lower limit of normal; ULN, upper limit of normal; TFI, treatment-free interval; CI, confidence interval; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; CRP, C-reactive protein; NLR, neutrophil/lymphocyte ratio; PLR, platelet/ lymphocyte ratio; TKI, tyrosine kinase inhibitor.
analysis in relation to OS showed anaemia, thrombocytosis, neutrophilia, <1 year from diagnosis to first-line-targeted treatment, hypercalcaemia and high NLR were independent factors in the new model. Only hypercalcaemia (HR = 1.76), <1 year from diagnosis to first-line-targeted treatment (HR = 2.24), neutrophilia (HR = 1.99) and high NLR (HR = 1.65) were significant in the multivariable analysis (P < 0.05, Table 2 ). High C-reactive protein, erythrocyte sedimentation rate and PLR were significant prognostic factors in the univariate analysis but not in the multivariable analysis (P > 0.05).
We recorded all six prognostic factors for the 190 patients for analysis and included them in the risk stratification using the new criteria (Table 3 ). The new model significantly separated between the four risk groups, as shown in Fig We then compared the new model with the five-factor Heng model ( Table 4 In the new model, 14% of the 12-month alive patients were reclassified into a higher risk category and 38% were reclassified into a lower risk category, with a net reclassification index (NRI) of 24.5% (27 of 110 patients). Among the patients who died at 12 months, 22.5% were reclassified into a higher risk category and 10% were reclassified into a lower risk category, with an NRI of 12.5% (10 of 80 patients). The total overall net reclassification improvement with the addition of NLR was 61.4% (P ≤ 0.001, Table 4 ).
Discussion
This study showed the prognostic significance of neutrophils and the NLR in mRCC cohorts treated with systemic therapy. The increased NLR exhibited a relatively worse survival prognosis and increased the potential for tumour progression (11) . The NLR is believed to be a potential indicator of host immune and neutrophil-dependent tumourigenesis, as well as inflammation induced by T cell function (12) . The close relationship between inflammation and cancer progression is evident in the tumour microenvironment interaction with host inflammatory cells, including neutrophils (13) . Circulating and tumour-associated neutrophils are the major inflammatory and prognostic component of RCC that is included in the risk classification of the Heng risk model for mRCC (1, 11) . The NLR is a combination of inflammatory parameters that has an absolute value comparing neutrophils, which shows its prognostic role in localized RCC and mRCC (14) . Several recent studies, including meta-analyses, have shown robust responses when assaying the NLR in patients with mRCC treated with targeted therapy (11, 15) . Given that TKIs exert antiangiogenic and immunomodulatory effects such as neutrophil migration and T lymphocyte-dendritic cell crosstalk (15) , the implications of the NLR in mRCC patients receiving targeted therapy may have more significance than in the RCC patient population as a whole. Other retrospective studies of patients with localized clear-cell RCC, who underwent either nephrectomy or embolization, also showed that the preoperative NLR and its postoperative change were associated with a significant increase in the risk of local recurrence and distant metastasis (16, 17) . The early NLR decrease was associated with favourable OS and progression-free survival, whereas its increase was associated with an unfavourable outcome (11, 17) .
The NLR is closely related to metastatic organ status, which results in different survival outcomes. Teishima et al. grouped the patients with mRCC into extrapulmonary and non-extrapulmonary metastatic groups (18) and found that a high pretreatment NLR > 3.0 was an independent risk factor for progression-free survival in the patients with extrapulmonary metastasis, while no significant difference in progression-free survival was observed in the high-or low-NLR groups in patients with no extrapulmonary metastases. Several other studies also showed poor outcomes in the cases of either liver, brain or bone metastases (19, 20) , and a favourable outcome in cases with pulmonary metastasis (21) . This shows the potential role of NLR in prognostication of therapeutic responses to targeted therapy in mRCC according to metastatic sites.
This study applied the NLR by dividing the three risk groups into four newly differentiated prognostic risk groups by adding the NLR to the Heng risk model to increase its accuracy in predicting OS (C-statistic = 0.6540 vs. 0.5797, P < 0.001). Although the Heng risk model is the standard for prognostication in patients with mRCC treated with targeted therapy, in the absence of a validated prognostic biomarker for mRCC, the NLR factor shows independent prognostic significance in both univariate and multivariable analyses This result is the likely explanation for the statistical improvement we observed and the increased accuracy of the Heng risk model, with 25.8% of patients classified into more appropriate risk groups (Table 4 ). This new prognostic classification was better able to distinguish between the 'good' and 'intermediate' risk groups by extending the risk classification to include a 'good-intermediate' risk group, as well as to improve the prognostic ability of the Heng model by its addition of the NLR factor.
Previous studies attempted to discover new prognostic risk factors to enhance the accuracy of prognostication in mRCC and to add these factors into prognostic risk models for better prognoses predictions (13, 21) . Tanaka et al. (13) and Motzer et al. (21) showed that for mRCC patients treated with targeted therapy, the replacement of neutrophils by the NLR or PDL1 factors improved the predictive accuracy of prognoses, similar to this study. Sella et al. focused on the heterogenous intermediate risk group to better reflect the prognostic outcome with haemoglobin and an interval time of <1 year since diagnosis (22) . Thiery-Vuillemin et al. showed that metastasectomy, absence of LN metastasis, duration of disease control, and MSKCC intermediate risk, were better predictive factors for therapeutic outcomes after first-and second-line-targeted therapy in favourable and intermediate mRCC risk groups (23) . These risk factors could aid clinicians in better treatment decision-making, which can build a better treatment strategy and counselling for patients with mRCC of sequential treatments in the targeted therapy era.
Finally, some differential baseline characteristics might be noticed in this study such as inclusion of a large percentage of patients aged <60 years, with the median OS being less than expected with currently used treatments (>30 months). The explanation of the greater percentage of patients aged <60 years is the geographic differences and a national policy programme. The national cancer screening programme administered by the Korean government gave all Koreans aged at least 50 years an opportunity to have their general health examined, including abdominal ultrasonography, which may lead to patients being diagnosed routinely in their 50s and 60s (24) . The median OS of this study seemed to be less than expected in clinical trials, whereas other mRCC studies, including some Japanese studies, reported similar results to our study. In terms of the OS in patients treated with cytokines, it was similar to Japanese data that indicated an OS of 46 months in the favourable outcome group. Motzer et al. also reported that the favourable, intermediate, and poor risk group had OSs of 29.6 months, 13.8 months, and 4.9 months, respectively (25) . In addition, Heng et al. reported the favourable, intermediate and poor risk groups did not reach a median OS at 27 and 8.8 months, respectively (1). In typical clinical settings, a median OS of >30 months was shown in a phase 3 clinical trial in which 95% of patients underwent nephrectomy, and patients with brain metastasis were all excluded from the trial. Therefore, in typical clinical scenarios, the median OS of mRCC treated with systemic therapy was shorter than the median OS of 30 months. Lee et al. showed in a comparative survival analysis of mRCC between Asian and non-Asian patients that sunitinib efficacy was comparable between Asian and non-Asian patients, with an objective response rate of 18% vs. 14%; a median progression-free survival of 8.7 months vs. 10.9 months; and an OS of 18.9 months vs. 18.4 months, respectively (26) .
In addition to the potential limitations of a small-sized, retrospective study design using a single institution, the disproportionally small-sized risk groups and the inclusion of a small portion of patients treated with immunotherapy, which is no longer the standard of care, also restricts this study's impact. The lack of multiple diverse systemic treatment modalities and known prognostic factors of RCC, such as PS, LDH and genomic information (1, 27) , were some other weaknesses of the current study. We excluded PS (ECOG-PS) from the analysis. And this could be a limitation in this study. However, first, our data were not Karnofsky performance status of the Heng model, and almost all (97%) patients were PS 0. This is why PS excluded from the analysis. The cut-off level of NLR was an issue in this study since no standard guidelines currently exist for the selection of NLR cut-off values. This study chose a median NLR cut-off level derived from the cohort samples, whereas other multiple studies have employed various cut-off values (2.5-4.0) (11, 14) . The prognostic significance of these various NLR cut-off values have been previously determined using a dichotomous NLR variable in the analyses. However, similar to this study, all of these studies showed that a higher NLR was associated with a poor prognosis. Future prospective studies with more specific cut-off levels, targeted treatment risk groups, and primary and secondary targeted treatment groups are required to evaluate the impact of NLR in terms of prognostic outcomes.
The study therefore showed the prognostic significance of the NLR for OS in patients with mRCC treated with systemic therapy that it might be a good predictor of therapeutic responses before and after systemic treatment. The NLR also significantly increased the accuracy of established prognostic factors (Heng risk criteria), and we suggest it as a new additional prognostic risk factor in the Heng risk model with new classified risk groups.
The addition to, or replacement by, the NLR aids clinicians in deciding further therapeutic strategies (e.g. in patients whose tumours have slightly increased on imaging to stable disease status, with a decline in the NLR). Furthermore, the NLR might also be a useful tool for selecting optimal treatment regimens, such as blockade of the programmed cell death protein 1 (28) . Using the new model with the NLR, we observed statistically better discriminatory ability than the existing Heng risk model.
Materials and methods
Ethical statements
This retrospective study was approved by the Institutional Review Board of the National Cancer Center (No. NCC2015-0087) and received exemption for the need for written consent. Patient data were anonymized and de-identified prior to analysis. Study procedures were performed in accordance with the ethics of the declaration of Helsinki.
Study design and patients
Between April 2007 and July 2014, the medial records of 190 consecutive patients with mRCC treated with systemic immunotherapy including cytokines and vascular endothelial growth factor (VEGF)-targeted therapy were retrospectively collected, including 72 (39%) patients who received only systemic immunotherapy [interferonalpha and/or interleukin (IL)-2], 40 (21%) patients who received systemic immunotherapy prior to VEGF-targeted therapy, and 78 (40%) patients who received only VEGF-targeted therapy (sorafenib, sunitinib, pazopanib or axitinib). The enroled patients had neither a history of recent surgery, cerebrovascular disease, infectious disease, any disease treated with steroids, nor any other secondary predisposing malignancy. All baseline demographics and clinical and laboratory data, including baseline systemic inflammatory markers, were prospectively collected on the kidney cancer database and retrospectively selected for the study. All diagnoses of RCC were based on the histological analysis of specimens obtained at nephrectomy, renal biopsies and/or biopsies taken from metastatic sites. Dose reduction was permitted based on individual tolerability. Each drug was continued until the development of disease progression, unacceptable toxicity or physician's discretion.
Venous blood sampling was conducted within one week before the patients underwent first therapy.
Assessment of response
Responses were evaluated using RECIST criteria. Complete response was defined as the disappearance of all evidence of disease. Partial response was defined as ≥30% reduction in unidimensional tumour measurements, without the appearance of any new lesions or the progression of any existing lesion. Progressive disease was defined as any of the following: 20% increase in the sum of the products of all measurable lesions, appearance of any new lesion or reappearance of any lesion that had previously disappeared. Stable disease was defined as a tumour response not fulfilling any of the above criteria.
Statistical analyses
OS was calculated from the date of initiation of therapy to the date of death. Patients who were alive at the last follow-up were censored at that time. The association of each marker with OS was analysed using Kaplan-Meier plots, the log-rank test and Cox proportional hazards model, and associated 95% CIs were calculated.
We individually examined the impact of each of the baseline markers of systemic inflammation (albumin, neutrophils, lymphocytes, platelets, NLR and PLR) on OS. These markers were analysed as categorical variables. Dichotomization of these variables was based on the upper (neutrophils and platelets) or lower (albumin and lymphocytes) ranges of normal measurements for these markers.
For NLR and PLR, no widely accepted cut-off point has been adopted in previous studies (11, 14) ; therefore, we used the medians of distribution as cut-off points for dichotomization. We then built a multivariable model by using the Cox model to combine markers of systemic inflammation and Heng risk factors. With the Heng model variable fixed, all inflammatory factors except heavy missing (≥20%) were included in the backward stepwise elimination procedure (alpha = 0.1). The final multivariable model retained all Heng risk factors except ECOG-PS, and only the markers of systemic inflammation with a P value <0.1 were retained.
Patients were then reclassified into four risk groups (favourable, good-intermediate, intermediate and poor) using the new classification based on the presence of baseline factors identified to be significant in the final model. We compared the concordance statistics (C-statistic) (29) of the two prognostic classifications (Heng classification and new classification with Heng risk factors and markers of systemic inflammation) and risk factors. We used the likelihood ratio test to assess whether the new model fit significantly better than the Heng model. Kaplan-Meier curves were used to illustrate the differences in survival distribution for the different prognostic groups.
The incremental benefit of adding markers of systemic inflammation to the Heng risk factors to improve prognostic classification was also evaluated by calculating the NRI (30) . First, patients were stratified into one risk category using the Heng classification (1). Then, we used the new classification (Heng risk factors with the NLR) to determine the risk category to ascertain whether there would be improvement in the NRI; that is, whether the patients who died would be assigned to a higher risk category and those who survived to a lower risk category.
All statistical tests were two-sided, and a P < 0.05 was considered statistically significant. Analyses were performed using STATA version 14 (StataCorp LP, College Station, Texas).
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